Sacituzumab govitecan has received a breakthrough therapy designation by the U.S. FDA for patients with extensive-stage SCLC in the second line. #LCSM #MedTwitter #Oncology Read here: onclive.com/view/fda-grant…

Honored to help nominate Andrea Apolo, M.D. as an excellent mentor and sponsor on our career paths!

Is it time to re-classify urachal cancer as a GI rather than a GU malignancy? In npj Journals Precision Oncology, we show the genomic profile of this rare cancer is more similar to colorectal than bladder cancer. (1/2) Link: nature.com/articles/s4169…

Sharing this Bladder Cancer Advocacy Network BCAN Survey for bladder cancer patients!

Dr Andrea Apolo, M.D. National Cancer Institute has executed phenomenal innovative investigator-initiated clinical trials in rare GU/Bladder Cancer Variants. She takes the stage at #AUC3 to educate us all! Jonathan Rosenberg MD Sumanta K. Pal, MD, FASCO Rana McKay, MD, FASCO

A video highlighting the work at the NIH, especially in rare diseases (even beyond cancer!), from the patient perspective. Even more proud that it features the work of my superstar wife Carolina Montaño MD,PhD with Hopkins mentor Nara Sobreira instagram.com/reel/DG07hr8Sw…

“Outstanding Mentor award” is one of the most important awards I have received. ❤️ Pay it forward! Thank you to my mentees for the nomination Saad Atiq Dr. Andre R. Kydd National Cancer Institute NIH NIH Clinical Center NIH Intramural Alliance for Clinical Trials in Oncology Bladder Cancer Advocacy Network open.spotify.com/episode/7AtvHO…

Results from OptiTROP-B01 out in Nature Medicine. The TROP2-ADC sacituzumab tirumotecan improved PFS and OS in highly pretreated mTNBC, irrespective of Trop2 exp. Results similar to ASCENT. Approved in China, may soon also reach the west (4th topo1 ADC). nature.com/articles/s4159…

Very proud of our own Saad Atiq National Cancer Institute senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the #Bladder showing 1/3 of patients with TMB-High ASCO #ASCO25 Caris Life Sciences

Andrea Apolo, M.D. Saad Atiq National Cancer Institute ASCO Caris Life Sciences Elias Chandran, MBBS Matt Galsky Nicholas Simon IBCG Bladder Cancer Bladder Cancer Advocacy Network Ravi A Madan M.D. Fatima Karzai, M.D. Dr. Andre R. Kydd Giovanni Maria Iannantuono We would like to inform you that your post has been published on OncoDaily. Thank you for sharing such valuable content. oncodaily.com/url/306404

Opening soon at the NIH!! E-VIRTUE, A Phase 2 Trial of Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors. Andrea Apolo, M.D. National Cancer Institute Nicholas Simon Dr. Andre R. Kydd Saad Atiq doi.org/10.1080/147966…

Proud to share this summary from #asco2025, segment on renal, bladder and prostate cancers from Oncology Brothers discussion with Enrique Grande and Petros Grivas - article co-authored with Saad Atiq oncupdates.com/article/breakt…!

Yes! Congratulations to all! And a big shout out to our own Miles Hsu NCI CCR GU Malignancies NIH Bladder Cancer Advocacy Network #EndBladderCancer

#BCANTT25 proud of our Medical Oncology fellow Miles Hsu who received the the 2025 John Quale Travel award for our work in the development of a clinical trial for bladder preservation in MIBC. Congratulations to him and to all the outstanding fellows! Bladder Cancer Advocacy Network

The future of bladder cancer is in great hands. 👏 Stellar class of 2025 John Quale Travel Fellows! Bladder Cancer Advocacy Network #BCANTT25

Wonderful insights from clinical trials - both positive and negative, with pros and cons- at Bladder Cancer Advocacy Network #bcantt25 co-chaired by Andrea Apolo, M.D. NCI CCR GU Malignancies and Seth Lerner Jonathan Rosenberg MD Jean Hoffman-Censits Parminder singh

A striking wrap-up by Andrea Apolo, M.D. and team: 2024’s top 5 advances in #BladderCancer: 1️⃣TAR-200 intravesical drug delivery 2️⃣Adjuvant ICI doubles DFS in high-risk MIBC 3️⃣Periop durvalumab boosts EFS & OS 4️⃣ctDNA to guide adjuvant ICI 5️⃣Enfortumab vedotin + pembro = new 1L

Proud to share our latest on recent advances and progress in treating Bladder Cancer with the Andrea Apolo, M.D. group! Saad Atiq Nicholas Simon Elias Chandran, MBBS NCI CCR GU Malignancies doi.org/10.1002/cncr.7…

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…

The outlook for the #BladderCancer field is undoubtedly positive as the field builds upon an excellent foundation of novel therapeutics and drug delivery mechanisms. Hear more from Andrea Apolo, M.D., lead author of a new commentary in Cancer: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert